Advancing stabilized isoamyl nitrite for intranasal treatment of cyanide exposure

Ended Definitive Contract Awarded Last action

Contract number
HHSO100201700001C
Awardee
Awarding agency
Obligated
$32,952,759

Award facts

Opportunity
  • BAA16100SOL00001 Solicitation number
Contract value 45% obligated
  • $32,952,759.00 Current, with exercised options
  • $73,947,282.00 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Montgomery Village, MD 20879, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00018 · Extend contract to allow delivery of phase 1 clinical study report $0
Other Administrative Action P00017 · DE-scope EOP1 and no deliverables to be provided to barda $0
Other Administrative Action P00016 · Put a stop to tasks that are no longer needed $0
Other Administrative Action P00015 $0
Other Administrative Action P00014 · Update period of performance for clin 0003 $0
Other Administrative Action P00013 · Update key personnel $0
Other Administrative Action P00012 · Add hhsar clause 352.232-71 and IPP language $0
Funding Only Action P00011 · Add additional funding to clin 0003 and extend POP to 4/30/24 $6,814,323
Other Administrative Action P00010 · Incorporate far deviation clause 52.223-99, ensuring adequate covid safety protocols for federal contractors $0
Other Administrative Action P00009 · Replace CS and COR $0
Supplemental Agreement for work within scope P00008 $0
Other Administrative Action P00007 · Extend period of performance of clin 0001 from 10/31/2020 to 12/31/2020. $0
Other Administrative Action P00006 · Extend period of performance of clin 0001 from 7/31/2020 to 10/31/2020. $0
Other Administrative Action P00005 · Extend period of performance of clin 0001 from 12/31/2019 to 7/31/2019. $0
Exercise an Option P00004 · Exercise option 2 (clin 0003), revise article b.2, b.3 and b.5.a.2 and revise / replace statement of work. $11,985,234
Supplemental Agreement for work within scope P00003 $1,465,120
Other Administrative Action P00002 $0
Other Administrative Action 1 $0
Original award $12,688,082
Show all 19

About this award

Written by GovTribe AI ·

The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response awarded a $73,947,282.00 cost-plus-fixed-fee definitive contract to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer, to advance the development of stabilized isoamyl nitrite for intranasal treatment of cyanide exposure. The contract, which does not have a set-aside designation, has a completion date of July 25, 2025. Emergent Product Development Gaithersburg Inc. is a well-established federal contractor, having received over $1.3 billion in prime contracts from HHS and the Department of Defense since 2019 for various medical countermeasures and pharmaceutical products.

Quick answers

Who was awarded contract HHSO100201700001C?

HHSO100201700001C was awarded to Emergent Product Development Gaithersburg Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 15, 2017.

How much is contract HHSO100201700001C worth?

The government has obligated $32,952,759 on HHSO100201700001C. Its potential value, with all options, is $73,947,282.

Was contract HHSO100201700001C competed?

The extent of competition for HHSO100201700001C was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login